ORIC Oric Pharmaceuticals Inc

Price (delayed)

$8.55

Market cap

$576.46M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.81

Enterprise value

$520.1M

ORIC Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist ...

Highlights
The quick ratio has surged by 105% since the previous quarter and by 63% year-on-year
Oric Pharmaceuticals's equity has surged by 62% YoY and by 47% QoQ
ORIC's net income is down by 13% year-on-year

Key stats

What are the main financial stats of ORIC
Market
Shares outstanding
67.42M
Market cap
$576.46M
Enterprise value
$520.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$101.76M
EBITDA
-$100.72M
Free cash flow
-$96M
Per share
EPS
-$1.81
Free cash flow per share
-$1.43
Book value per share
$4.88
Revenue per share
$0
TBVPS
$5.21
Balance sheet
Total assets
$350.79M
Total liabilities
$22.14M
Debt
$0
Equity
$328.65M
Working capital
$308.87M
Liquidity
Debt to equity
0
Current ratio
21.31
Quick ratio
20.83
Net debt/EBITDA
0.56
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-34.8%
Return on equity
-38.1%
Return on invested capital
-45.7%
Return on capital employed
-30.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ORIC stock price

How has the Oric Pharmaceuticals stock price performed over time
Intraday
-2.84%
1 week
-6.66%
1 month
5.82%
1 year
66.02%
YTD
-7.07%
QTD
-37.82%

Financial performance

How have Oric Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$114.09M
Net income
-$101.76M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 21% year-on-year and by 3% since the previous quarter
ORIC's net income is down by 13% year-on-year

Growth

What is Oric Pharmaceuticals's growth rate over time

Valuation

What is Oric Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 17% year-on-year and by 8% since the previous quarter
Oric Pharmaceuticals's equity has surged by 62% YoY and by 47% QoQ
The stock's P/B is 24% less than its 5-year quarterly average of 2.3 and 8% less than its last 4 quarters average of 1.9

Efficiency

How efficient is Oric Pharmaceuticals business performance
Oric Pharmaceuticals's return on invested capital has increased by 13% QoQ and by 10% YoY
The return on equity is up by 11% since the previous quarter and by 7% year-on-year
The ROA is up by 10% since the previous quarter and by 6% year-on-year

Dividends

What is ORIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORIC.

Financial health

How did Oric Pharmaceuticals financials performed over time
The quick ratio has surged by 105% since the previous quarter and by 63% year-on-year
The company's current ratio has surged by 105% QoQ and by 64% YoY
ORIC's debt is 100% smaller than its equity
Oric Pharmaceuticals's equity has surged by 62% YoY and by 47% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.